View in EDS HTML Full Text PDF Full Text

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.

Saved in:

Bibliographic Details
Title:	Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Authors:	Strober, Bruce¹ (AUTHOR), Armstrong, April² (AUTHOR), Rubant, Simone³ (AUTHOR), Patel, Manish³ (AUTHOR), Wu, Tianshuang³ (AUTHOR), Photowala, Huzefa³ (AUTHOR), Crowley, Jeffrey⁴ (AUTHOR)
Source:	Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p2991-2996. 6p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	09546634
DOI:	10.1080/09546634.2022.2095328